Alzheimer's disease (AD) is an age-related neurodegenerative disorder that accounts for numerous deaths worldwide. AD is the most common cause of dementia, characterized by accumulation of fibrous amyloid beta protein in the brain with clinical symptoms, such as loss of intellectual and social skills, gradually leading to the death of brain cells. The genetic complexity of AD during disease progression requires a systems-level understanding to design viable therapeutics. We present an integrative computational analysis to prioritize AD-associated genes outlined through a protein–protein interaction network. Multiple topological parameters of the network were considered to target proteins which are accountable for disease susceptibility. Furthermore, in silico protein structure modeling and molecular dynamics simulation approaches were implemented to characterize presenilin 2 (PSEN2) protein as one of the leading targets in the network. The findings are constructive to aid future drug discovery endeavors in the treatment of AD.
BaiXC, YanC, YangG, et al. (2015). An atomic structure of human γ-secretase. Nature, 525, 212–217.
3.
BalastikM, LimJ, PastorinoL, and LuKP. (2007). Pin1 in Alzheimer's disease: Multiple substrates, one regulatory mechanism?. Biochim Biophys Acta, 1772, 422–429.
4.
BaoG, KammRD, ThomasW, et al. (2010). Molecular biomechanics: The molecular basis of how forces regulate cellular function. Cell Mol Bioeng, 3, 91–105.
5.
BarabásiAL, and BonabeauE. (2003). Scale-free networks. Sci Am, 288, 60–69.
6.
Bauer-MehrenA, BundschusM, RautschkaM, MayerMA, SanzF, and FurlongLI. (2011). Gene-disease network analysis reveals functional modules in mendelian, complex and environmental diseases. PLoS One, 6, e20284.
7.
BeechamGW, HamiltonK, NajAC, et al. (2014). Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias. PLoS Genet, 10, e1004867.
8.
BiegingKT, MelloSS, and AttardiLD. (2014). Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer, 14, 359–370.
9.
BerendsenHJC, PostmaJPM, GunsterenWFV, DiNolaA, and HaakJR. (1984). Molecular dynamics with coupling to an external bath. J Chem Phys, 81, 3684–3690.
10.
BerendsenHJC, SpoelDVD, and DrunenRV. (1995). GROMACS: A message-passing parallel molecular dynamics implementation. Comput Phys Commun, 91, 43–56.
11.
BlauwendraatC, WilkeC, JansenIE, et al. (2016). Pilot whole-exome sequencing of a German early-onset Alzheimer's disease cohort reveals a substantial frequency of PSEN2 variants. Neurobiol Aging, 37, 208.e11–208.e17.
12.
BlayneyJK, ZhengH, WangH, and AzuajeF. (2010). Multi-level integrative analysis of protein–protein interaction networks: Connecting completeness, depth and robustness. Int J Comput Biol Drug Des, 3, 31–51.
13.
BlennowK, deLeonHJ, and ZatterbergH. (2006). Alzheimer's disease. Lancet, 368, 387–403.
14.
BowersKJ, ChowE, XuH, et al. (2006). Scalable algorithms for molecular dynamics simulations on commodity clusters. Proceedings of the ACM/IEEE Conference on Supercomputing, Article No. 84. Nov. 11–17, 2006, Tampa, FL. Page 43.
15.
CaiY, AnSSA, and KimSY. (2015). Mutations in presenilin 2 and its implications in Alzheimer's disease and other dementia-associated disorders, Clin Interv Aging, 10, 1163–1172.
16.
ChangJR, GhafouriM, MukerjeeR, BagashevA, ChabrashviliT, and SawayaBE. (2012). Role of p53 in neurodegenerative diseases. Neurodegener Dis, 9, 68–80.
17.
Chatr-AryamontriA, OughtredR, BoucherL, et al. (2016). The BioGRID interaction database: 2017 update. Nucleic Acids Res, 45,(Database issue),D369–D379.
18.
ChenJY, ShenC, and SivachenkoAY. (2006). Mining Alzheimer disease relevant proteins from integrated protein interactome data. Pac Symp Biocomput, 11, 367–378.
19.
ChiLM, WangX, and NanGX. (2016). In silico analyses for molecular genetic mechanism and candidate genes in patients with Alzheimer's disease. Acta Neurol Belg, 116, 543–547.
20.
ChomaC, GratkowskiH, LearJD, and DeGradoWF. (2000). Asparagine-mediated self-association of a model transmembrane helix. Nat Struct Biol, 7, 161–166.
21.
CitronM. (2010). Alzheimer's disease: Strategies for disease modification. Nat Rev Drug Discov, 9, 387–398.
22.
ColovosC, and YeatesTO. (1993). Verification of protein structures: Patterns of nonbonded atomic interaction. Protein Sci, 2, 1511–1519.
23.
DartnellL, SimeonidisE, HubankM, TsokaS, BogleIDL, and PapageorgiouLG. (2005). Robustness of the p53 network and biological hackers. FEBS Lett, 579, 3037–3042.
24.
DasSK, PalS, and GhosalMK. (2012). Dementia: Indian scenario. Neurol India, 60, 618–624.
25.
DeSB, IwatsuboT, and WolfeMS. (2012). Presenilins and γ-secretase: Structure, function, and role in Alzheimer disease. Cold Spring Harb Perspect Med, 2, a006304.
26.
DeLanoWL. (2002). The PyMOL Molecular Graphics System, Version 1.7.4. Schrödinger, LLC.
27.
FengY, WangQ, and WangT. (2017). Drug target protein–protein interaction networks: A systematic perspective. BioMed Res Int [Epub ahead of print]; DOI: 10.1155/2017/1289259.
28.
GoateA, Chartier-HarlinMC, MullanM, et al. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature, 349, 704–706.
29.
GrueningerF, BohrmannB, CzechC, et al. (2010). Phosphorylation of Tau at S422 is enhanced by Abeta in Tau PS2APP triple transgenic mice. Neurobiol Dis, 37, 294–306.
30.
GuerreiroRJ, GustafsoncDR, and HardyJ. (2012). The genetic architecture of Alzheimer's disease: Beyond APP, PSENs and APOE. Neurobiol Aging, 33, 437–456.
31.
GuexN, and PeitschMC. (1997). SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis, 18, 2714–2723.
32.
HallockP, and ThomasM. (2012). Integrating the Alzheimer's disease proteome and transcriptome: A comprehensive network model of a complex disease. OMICS, 16, 37–49.
33.
HardyJA. (2006). Hundred years of Alzheimer's disease research. Neuron, 52, 3–13.
34.
HawrylyczMJ, LeinES, Guillozet-BongaartsAL, et al. (2012). Allen human brain atlas-an anatomically comprehensive atlas of the adult human transcriptome. Nature, 489, 391–399.
35.
HubbardRE, and KamranHM. (2010). Hydrogen bonds in proteins: Role and strength. Encyclopedia of Life Sciences (eLS). [Epub ahead of print]; DOI: 10.1002/9780470015902.a0003011.pub2.
HwangDY, ChaeKR, KangTS, et al. (2002). Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer's disease. FASEB J, 16, 805–813.
38.
JamalS, GoyalS, ShankerA, and GroverA. (2016). Integrating network, sequence and functional features using machine learning approaches towards identification of novel Alzheimer genes. BMC Genomics, 17, 807.
39.
JayadevS, LeverenzJB, SteinbartE, et al. (2010). Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain, 133,(Pt 4),1143–1154.
40.
JorgensenWL, and MaduraJD. (1985). Temperature and size dependence for Monte Carlo simulations of TIP4P water. Mol Phys, 56, 1381–1392.
41.
JorgensenWL, MaxwellDS, and RivesJT. (1996). Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc, 118, 11225–11236.
42.
JourquinJ, DuncanD, ShiZ, and ZhangB. (2013). GLAD4U: Deriving and prioritizing gene lists from PubMed literature. BMC Genomics 13(Suppl 8),S20.
43.
KopanR, and GoateA. (2000). A common enzyme connects Notch signaling and Alzheimer's disease. Genes Dev, 14, 2799–2806.
44.
LaskowskiRA, MacArthurMW, MossDS, and ThorntonJM. (1993). PROCHECK: A program to check the stereochemical quality of protein structures. J Appl Crystallogr, 26, 283–291.
45.
LawV, KnoxC, DjoumbouY, et al. (2014). DrugBank 4.0: Shedding new light on drug metabolism. Nucleic Acids Res, 42, D1091–D1097.
46.
LearJD, GratkowskiH, AdamianL, LiangJ, and DeGradoWF. (2003). Position-dependence of stabilizing polar interaction of asparagine in transmembrane helical bundles. Biochemistry, 42, 6400–6407.
47.
LeeJH, and GonzalezGH. (2011). Towards Integrative gene prioritization in Alzheimer's disease. Pac Symp Biocomput. 4–13.
48.
LeeTH, ChenCH, SuizuF, et al. (2011). Death-associated protein kinase 1 phosphorylates Pin1 and inhibits its prolyl isomerase activity and cellular function. Mol Cell, 42, 147–159.
49.
Levy-LahadE, WascoW, PoorkajP, et al. (1995). Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science, 269, 973–977.
50.
LiM, WangJX, WangH, and PanY. (2013). Identification of essential proteins from weighted protein–protein interaction networks. J Bioinform Comput Biol, 11, 1341002.
51.
LiMJ, LiuZ, WangP, et al. (2016). GWASdb v2: An update database for human genetic variants identified by genome-wide association studies. Nucleic Acids Res, 44,(D1),D869–D876.
52.
LiuDC, and NocedalJ. (1989). On the limited memory BFGS method for large scale optimization. Math Program, 45, 503–528.
53.
MacArthurJ, BowlerE, CerezoM, et al. (2017). The new NHGRI-EBI catalog of published genome-wide association studies (GWAS Catalog). Nucleic Acids Research, 45,(Database issue),D896–D901.
54.
MalhotraA, YounesiE, SahadevanS, ZimmermannJ, and ApitiusMH. (2015). Exploring novel mechanistic insights in Alzheimer's disease by assessing reliability of protein interactions. Sci Rep, 5, 13634.
55.
NakanishiA, MinamiA, KitagishiY, OguraY, and MatsudaS. (2015). BRCA1 and p53 tumor suppressor molecules in Alzheimer's disease. Int J Mol Sci, 16, 2879–2892.
56.
OzmenL, AlbientzA, CzechC, and JacobsenH. (2009). Expression of transgenic APP mRNA is the key determinant for beta-amyloid deposition in PS2APP transgenic mice. Neurodegener Dis, 6, 29–36.
57.
PengQ, and SchorkNJ. (2014). Utility of network integrity methods in therapeutic target identification. Front Genet, 5, 12.
58.
Pletscher-Frankild, PallejàA, TsafouK, BinderJX, and JensenLJ. (2015). DISEASES: Text mining and data integration of disease–gene associations. Methods, 74, 83–89.
59.
PodderA, JatanaN, and LathaN. (2014). Human dopamine receptors interaction network (DRIN): A systems biology perspective on topology, stability and functionality of the network. J Theor Biol, 357, 169–183.
60.
RademakersR, CrutsM, and Van BroeckhovenC. (2003). Genetics of early-onset Alzheimer dementia. ScientificWorldJournal, 3, 497–519.
61.
RaoBS, GuptaKK, KaranamP, and PeruriA. (2014). Alzheimer disease: An interactome of many diseases. Ann Indian Acad Neurol, 17, 48–54.
62.
Rezaei-TaviraniM, Zamanian-AzodiM, RajabiS, Masoudi-NejadA, Rostami-NejadM, and RahmatiradS. (2016). Protein clustering and interactome analysis in Parkinson and Alzheimer's diseases. Arch Iran Med, 19, 101–109.
63.
RichardsJG, HigginsGA, OuagazzalAM, et al. (2003). PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci, 23, 8989–9003.
64.
RogaevEI, SherringtonR, RogaevaEA, et al. (1995). Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature, 376, 775–778.
65.
RogaevaE. (2002). The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease. Neuromol Med, 2, 1–10.
66.
RollandT, TaşanM, CharloteauxB, et al. (2014). A proteome-scale map of the human interactome network. Cell, 159, 1212–1226.
67.
RualJF, VenkatesanK, HaoT, et al. (2005).Towards a proteome-scale map of the human protein–protein interaction network. Nature, 437, 1173–1178.
68.
(2017). Schrödinger Release 2017-2: Maestro. New York: Schrödinger, LLC, 2017.
69.
ShannonP, MarkielA, OzierO, et al. (2003). Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res, 13, 2498–2504.
70.
SherringtonR, RogaevEI, LiangY, et al. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature, 375, 754–760.
71.
Soler-LópezM, ZanzoniA, LluísR, StelzlU, and AloyP. (2011). Interactome mapping suggests new mechanistic details underlying Alzheimer's disease. Genome Res, 21, 364–376.
72.
SzklarczykD, FranceschiniA, WyderS, et al. (2015). STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res, 43,(Database issue),D447–D452.
73.
SzklarczykD, SantosA, von MeringC, JensenLJ, BorkP, and KuhnM. (2016). STITCH 5: Augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res, 44,(D1),D380–D384.
74.
TakaloM, ViswanathanJ, NatunenT, et al. (2013). Regulation of key proteins in Alzheimer's disease molecular pathogenesis by ubiquilin-1. Mol Neurodegener 8 (Suppl 1),P20.
75.
TangY, LiM, WangJ, PanY, and WuFX. (2015). CytoNCA: A cytoscape plugin for centrality analysis and evaluation of protein interaction networks. Biosystems, 127, 67–72.
76.
UlmschneiderMB, and SansomMS. (2001). Amino acid distributions in integral membrane protein structures. Biochim Biophys Acta, 1512, 1–14.
77.
VasaikarSV, PadhiAK, JayaramB, and GomesJ. (2013). NeuroDNet—an open source platform for constructing and analyzing neurodegenerative disease networks. BMC Neurosci, 14, 3.
78.
VázquezA, DobrinR, SergiD, EckmannJP, OltvaiZN, and BarabásiAL. (2004). The topological relationship between the large-scale attributes and local interaction patterns of complex networks. Proc Natl Acad Sci U S A, 101, 17940–17945.
79.
VenkatesanK, RualJF, VazquezA, et al. (2009). An empirical framework for binary interactome mapping. Nat Methods, 6, 83–90.
80.
VonHG, and GavelY. (1988). Topogenic signals in integral membrane proteins. Eur J Biochem, 174, 671–678.
WalkerES, MartinezM, BrunkanAL, and GoateA. (2005). Presenilin 2 familial Alzheimer's disease mutations result in partial loss of function and dramatic changes in Abeta 42/40 ratios. J Neurochem, 92, 294–301.
83.
WangX, ThijssenB, and YuH. (2013). Target essentiality and centrality characterize drug side effects. PLoS Comput Biol, 9, e1003119.
84.
WeinerMW, VeitchDP, AisenPS, et al. (2015). Update of the Alzheimer's disease neuroimaging initiative: A review of papers published since its inception. Alzheimers Dement, 11, e1–e120.
85.
World Health Organization. (1998). Fact sheet No 135. Population ageing—a public health challenge. Geneva, Switzerland: World Health Organization. AccessedSeptember4, 2018. http://www.who.int/whr/1998/en/whr98_en.pdf
86.
YuH, TardivoL, TamS, et al. (2011). Next-generation sequencing to generate interactome datasets. Nat Methods, 8, 478–480.
87.
ZhangY. (2008). I-TASSER server for protein 3D structure prediction. BMC Bioinformatics, 40, 1–8.
88.
ZhengaH, WangaH, and AzuajebF. (2010). eNelator: A simulation system for large-scale vulnerability analysis of species-disease- and process-specific protein networks. J Comput Sci, 1, 197–205.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
